Business & Growth Update

Metropolis Healthcare Reports Strong Q1FY27 Business Update; Revenue Expected to Grow Around 16% YoY

NSE

metropolis

BSE

542650

Metropolis Healthcare Limited shared a business update for the quarter ended 30 June 2026, indicating approximately 16% year-on-year revenue growth driven by higher patient volumes and an improved product mix. The company also highlighted strong momentum in TruHealth Wellness, Specialty testing, and both B2C and B2B businesses, while EBITDA margins improved on a YoY basis.

PRICE-SENSITIVE TRIGGER

Event: Quarterly Business Update for Q1FY27.

Type: Business & Growth Update

Impact: Neutral

Immediate Effect: The company reported healthy demand trends and strong operating performance ahead of the announcement of its Q1FY27 financial results, indicating continued business momentum.

Key Metrics:

Revenue: Approximately 16% YoY growth
EBITDA: Not disclosed
PAT: Not disclosed
EBITDA Margin: Improved YoY; largely stable QoQ
QoQ Performance: EBITDA margins remained broadly stable
Segment Performance:
- TruHealth Wellness recorded strong growth.
- Specialty diagnostics emerged as one of the fastest-growing segments.

Highlight:

While detailed financial statements will be released after Board approval, the preliminary update suggests another quarter of healthy revenue growth supported by higher testing volumes and favourable business mix.

What Happened ?

Metropolis Healthcare issued a business update for the quarter ended 30 June 2026 under SEBI Listing Regulations.

The company stated that consolidated revenue is expected to grow by approximately 16% year-on-year, driven primarily by higher patient volumes and realization benefits from an improved product mix.

Management also highlighted healthy growth across both consumer and institutional businesses while maintaining stable operating profitability.

Key Details

Revenue Growth:

Consolidated revenue expected to increase by approximately 16% YoY.
Growth driven by:
- Higher patient volumes.
- Better realization through product mix improvements.

Segment Performance:

TruHealth Wellness was among the fastest-growing businesses.
Specialty diagnostics also recorded strong growth during the quarter.

Business Operations:

B2C

Healthy volume growth.
Higher throughput from the expanded diagnostic center network.

B2B

Growth supported by:
- Higher wallet share from existing customers.
- New customer acquisition.
- Improved service quality.
- Better delivery standards.

Operating Performance:

EBITDA margins improved on a year-on-year basis, in line with management guidance.
On a quarter-on-quarter basis, operating margins remained largely stable.

Additional Note:

The update is based on consolidated business performance.
Detailed Q1FY27 financial results will be announced after Board approval and remain subject to auditor review.

Risk Analysis

Summary:

The update is preliminary and does not include the complete financial statements.

Key Risks:

Revenue growth figures are indicative.
EBITDA and PAT numbers have not yet been disclosed.
Financial results remain subject to auditor review and Board approval.
Final reported numbers may differ from this business update.

Worst Case:

If final audited results differ materially from the preliminary update, investor expectations regarding revenue growth and profitability could be revised.

Risk Level: Low to Moderate

Company Commentary

Revenue expected to grow around 16% YoY.
TruHealth Wellness and Specialty segments delivered the fastest growth.
B2C and B2B businesses both recorded healthy volume expansion.
EBITDA margins improved YoY while remaining stable sequentially.
Detailed Q1FY27 financial results will be announced after Board approval.

Official Exchange Filing: Metropolis Healthcare Limited

Support our work by sharing